FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170352017> ?p ?o ?g. }

• W2170352017 endingPage "1688" @default.
• W2170352017 startingPage "1682" @default.
• W2170352017 abstract "Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood–brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT). A phase II trial assessing temozolomide 150 mg/m2/day, for 5 days every 28 days in primary central nervous system (CNS) lymphoma (PCNSL) patients with negative human immunodeficienct virus (HIV) serology, Eastern Cooperative Oncology Group (ECOG) performance status (PS)<4, previously treated with high-dose methotrexate-containing (HD-MTX) chemotherapy and/or RT was started. Twenty-three patients were enrolled. Median age was 60 years. Five complete remissions (median duration 6+ months; range 2–36 months), one partial response, four stable disease (median duration 7.2 months, range 2–16.5 months), and 13 progressions were observed. No major toxicities were observed, apart grade 3 vomiting in a single cycle. Main grade 1–2 toxicities were: 15% nausea, 6% vomiting, 9% fatigue and 9% neurological symptoms. This is the first prospective trial assessing single-agent activity in PCNSL at failure. Although some patients had a poor PS and had been heavily pre-treated, temozolomide yielded 26% objective responses and was well tolerated without any major toxicity." @default.
• W2170352017 created "2016-06-24" @default.
• W2170352017 creator A5000656122 @default.
• W2170352017 creator A5006549117 @default.
• W2170352017 creator A5008135397 @default.
• W2170352017 creator A5029031145 @default.
• W2170352017 creator A5036169694 @default.
• W2170352017 creator A5036985315 @default.
• W2170352017 creator A5038760660 @default.
• W2170352017 creator A5039006383 @default.
• W2170352017 creator A5049017377 @default.
• W2170352017 creator A5055907455 @default.
• W2170352017 creator A5063327760 @default.
• W2170352017 creator A5068500981 @default.
• W2170352017 creator A5085005133 @default.
• W2170352017 creator A5086792856 @default.
• W2170352017 creator A5087286496 @default.
• W2170352017 date "2004-07-01" @default.
• W2170352017 modified "2023-10-04" @default.
• W2170352017 title "Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial" @default.
• W2170352017 cites W1480166232 @default.
• W2170352017 cites W1480952979 @default.
• W2170352017 cites W182861671 @default.
• W2170352017 cites W1860711823 @default.
• W2170352017 cites W1959628099 @default.
• W2170352017 cites W1987104278 @default.
• W2170352017 cites W1992646418 @default.
• W2170352017 cites W1995821759 @default.
• W2170352017 cites W2029409133 @default.
• W2170352017 cites W2030260202 @default.
• W2170352017 cites W2050860382 @default.
• W2170352017 cites W2060244562 @default.
• W2170352017 cites W2112867037 @default.
• W2170352017 cites W2142855102 @default.
• W2170352017 cites W2149760873 @default.
• W2170352017 cites W2154647431 @default.
• W2170352017 cites W2159708587 @default.
• W2170352017 cites W2170487277 @default.
• W2170352017 cites W2186111039 @default.
• W2170352017 doi "https://doi.org/10.1016/j.ejca.2004.03.008" @default.
• W2170352017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15251157" @default.
• W2170352017 hasPublicationYear "2004" @default.
• W2170352017 type Work @default.
• W2170352017 sameAs 2170352017 @default.
• W2170352017 citedByCount "106" @default.
• W2170352017 countsByYear W21703520172012 @default.
• W2170352017 countsByYear W21703520172013 @default.
• W2170352017 countsByYear W21703520172014 @default.
• W2170352017 countsByYear W21703520172015 @default.
• W2170352017 countsByYear W21703520172016 @default.
• W2170352017 countsByYear W21703520172017 @default.
• W2170352017 countsByYear W21703520172018 @default.
• W2170352017 countsByYear W21703520172019 @default.
• W2170352017 countsByYear W21703520172020 @default.
• W2170352017 countsByYear W21703520172021 @default.
• W2170352017 countsByYear W21703520172022 @default.
• W2170352017 countsByYear W21703520172023 @default.
• W2170352017 crossrefType "journal-article" @default.
• W2170352017 hasAuthorship W2170352017A5000656122 @default.
• W2170352017 hasAuthorship W2170352017A5006549117 @default.
• W2170352017 hasAuthorship W2170352017A5008135397 @default.
• W2170352017 hasAuthorship W2170352017A5029031145 @default.
• W2170352017 hasAuthorship W2170352017A5036169694 @default.
• W2170352017 hasAuthorship W2170352017A5036985315 @default.
• W2170352017 hasAuthorship W2170352017A5038760660 @default.
• W2170352017 hasAuthorship W2170352017A5039006383 @default.
• W2170352017 hasAuthorship W2170352017A5049017377 @default.
• W2170352017 hasAuthorship W2170352017A5055907455 @default.
• W2170352017 hasAuthorship W2170352017A5063327760 @default.
• W2170352017 hasAuthorship W2170352017A5068500981 @default.
• W2170352017 hasAuthorship W2170352017A5085005133 @default.
• W2170352017 hasAuthorship W2170352017A5086792856 @default.
• W2170352017 hasAuthorship W2170352017A5087286496 @default.
• W2170352017 hasConcept C126322002 @default.
• W2170352017 hasConcept C141071460 @default.
• W2170352017 hasConcept C143998085 @default.
• W2170352017 hasConcept C2776694085 @default.
• W2170352017 hasConcept C2777389519 @default.
• W2170352017 hasConcept C2779338263 @default.
• W2170352017 hasConcept C2780580376 @default.
• W2170352017 hasConcept C2780852908 @default.
• W2170352017 hasConcept C2781059491 @default.
• W2170352017 hasConcept C2781173314 @default.
• W2170352017 hasConcept C31760486 @default.
• W2170352017 hasConcept C71924100 @default.
• W2170352017 hasConcept C90924648 @default.
• W2170352017 hasConceptScore W2170352017C126322002 @default.
• W2170352017 hasConceptScore W2170352017C141071460 @default.
• W2170352017 hasConceptScore W2170352017C143998085 @default.
• W2170352017 hasConceptScore W2170352017C2776694085 @default.
• W2170352017 hasConceptScore W2170352017C2777389519 @default.
• W2170352017 hasConceptScore W2170352017C2779338263 @default.
• W2170352017 hasConceptScore W2170352017C2780580376 @default.
• W2170352017 hasConceptScore W2170352017C2780852908 @default.
• W2170352017 hasConceptScore W2170352017C2781059491 @default.
• W2170352017 hasConceptScore W2170352017C2781173314 @default.
• W2170352017 hasConceptScore W2170352017C31760486 @default.
• W2170352017 hasConceptScore W2170352017C71924100 @default.

• next